Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03313778
Title Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (KEYNOTE-603)
Acronym KEYNOTE-603
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors ModernaTX, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | GBR | AUS

Additional content available in CKB BOOST